Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1993-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1210/JCEM.77.6.8263137PMID 8263137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of parathyroid hormone synthesis and secretion.

  1994cited by this paper
• Direct inhibitory effect of amino-terminal parathyroid hormone fragment [PTH(1-34)] on PTH secretion from bovine parathyroid primary cultured cells in vitro.

  1991cited by this paper
• Circadian variation in ionized calcium and intact parathyroid hormone: evidence for sex differences in calcium homeostasis.

  1991cited by this paper
• Parathyroid Hormone-(1-34) [PTH-(l-34)]: Demonstration of Suppression of Endogenous Secretion Using Immunoradiometric Intact PTH-(l-84) Assay*

  1991cited by this paper
• Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay.

  1991cited by this paper
• Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.

  1990cited by this paper
• Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations.

  1988cited by this paper
• Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D

  1986cited by this paper
• Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay.

  1985cited by this paper
• A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies.

  1984cited by this paper
• Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis.

  1984cited by this paper
• Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies

  1984cited by this paper
• Acute effects of parathyroid hormone on vitamin D metabolism in patients with the bone loss of aging.

  1982cited by this paper
• Assessment of 25-hydroxyvitamin D 1 alpha-hydroxylase reserve in postmenopausal osteoporosis by administration of parathyroid extract.

  1981cited by this paper
• Short-term effects of synthetic human parathyroid hormone-(1--34) administration on bone mineral metabolism in osteoporotic patients.

  1981cited by this paper
• Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients.

  1981cited by this paper
• Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

  1980cited by this paper
• Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis.

  1976cited by this paper
• Preliminary trial of low doses of human parathyroid hormone 1–34 peptide in treatment of osteoporosis

  1975cited by this paper
• A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum.

  1974cited by this paper
• ON THE STIMULATION OF NEW BONE-FORMATION WITH PARATHYROID EXTRACT AND IRRADIATED ERGOSTEROL

  1932cited by this paper

• Theranostic Approach for the Management of Osteoporosis.

  2023cites this paper
• Novel PTH gene mutations causing isolated hypoparathyroidism.

  2022cites this paper
• Use of parathyroid hormone analog (Teriparatide) in patients with chronic hypoparathyroidism after total thyroidectomy: a case report

  2020influential citation
• Dose Predictions for Drug Design.

  2020cites this paper
• Optimal administration frequency and dose of teriparatide for acceleration of biomechanical healing of long-bone fracture in a mouse model

  2019cites this paper
• Teriparatid – Das molekulare und klinische Profil bei der Therapie der Osteoporose

  2019cites this paper
• A computational study of the dual effect of intermittent and continuous administration of parathyroid hormone on bone remodeling.

  2019cites this paper
• Effect of Teriparatide in Postmenopausal Women with Osteoporosis

  2018cites this paper
• Dynamics of Bone Cell Interactions and Differential Responses to PTH and Antibody-Based Therapies

  2018cites this paper
• A case report of severe calciphylaxis – suggested approach for diagnosis and treatment

  2017cites this paper
• Understanding Mechanobiology: Physical Therapists as a Force in Mechanotherapy and Musculoskeletal Regenerative Rehabilitation

  2016cites this paper
• The Optimal Duration of PTH(1-34) Infusion Is One Hour per Day to Increase Bone Mass in Rats.

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Characteristics of Subcutaneously Applied PTH-1-37

  2016cites this paper
• Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women.

  2015cites this paper
• Understanding Mechanobiology: Physical Therapists as a Force in Mechanotherapy and Musculoskeletal Regenerative Rehabilitation

  2015cites this paper
• Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.

  2015cites this paper
• PTH(1-84) replacement therapy for the treatment of hypoparathyroidism

  2015cites this paper
• Molecular and Clinical Aspects of Pseudohypoparathyroidism

  2015cites this paper
• Effect of parathyroid hormone (PTH) in odontoblast-like cells and in the tertiary dentinogenesis in mice = : Efeito do hormônio paratireóideo (PTH) em linhagem de odontoblastos e na dentinogênese terciária em camundongos

  2014cites this paper
• Treadmill running reduces parathyroid hormone concentrations during recovery compared with a nonexercising control group.

  2014cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.

  2014cites this paper
• Effect of recovery duration between two bouts of running on bone metabolism.

  2013cites this paper
• Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety.

  2013cites this paper
• Use of parathyroid hormone in hypoparathyroidism

  2013influential citation
• Teriparatide

  2012cites this paper
• Screening for parathyroid hormone resistance in patients with nonphenotypically evident pseudohypoparathyroidism.

  2012cites this paper
• Osteoanabolics

  2012cites this paper
• An update on the clinical and molecular characteristics of pseudohypoparathyroidism

  2012cites this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.

  2012cites this paper
• Parathyroid Hormone in the Treatment of Osteoporosis

  2012cites this paper
• The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

  2011cites this paper
• Ronacaleret, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial.

  2011cites this paper
• Efeito da administração intermitente do hormônio paratireóideo (PTH) na formação de dentina em camundongos

  2011cites this paper
• The influence of parathyroid hormone treatment on implant fixation.

  2011cites this paper
• Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis.

  2011cites this paper
• Potential of the Osteoclast’s Proton Pump as a Drug Target in Osteoporosis

  2011cites this paper
• Recombinant parathormone and osteoporosis: a review article

  2010cites this paper
• Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide

  2009cites this paper
• Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

  2009cites this paper
• Reparação de enxertos ósseos autógenos recobertos ou não por membrana de ptfe-e em ratas ovariectomizadas. Estudo histológico e histomorfométrico

  2009cites this paper
• Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells.

  2009cites this paper
• Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats

  2009cites this paper
• Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation

  2009cites this paper
• Hypoparathyroidism: is it time for replacement therapy?

  2008cites this paper
• Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone

  2008influential citation
• ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.

  2008cites this paper
• Cellular Actions of Parathyroid Hormone

  2008cites this paper
• Pharmacological Mechanisms of Therapeutics: Parathyroid Hormone

  2008cites this paper
• CHAPTER 78 – Treatment with PTH Peptides

  2008cites this paper
• Combination Therapy Using Exercise and Pharmaceutical Agents to Optimize Bone Health

  2008cites this paper
• Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report.

  2007cites this paper
• Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

  2007cites this paper
• Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats.

  2006cites this paper
• CHAPTER 38 – Monitoring Anabolic Treatment

  2006cites this paper
• Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it?

  2006cites this paper
• Intermittent administration of human parathyroid fragment (hPTH 1-37) on calcium and phosphorus homeostasis and bone markers in resting horses: a preliminary study

  2005cites this paper
• Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.

  2005cites this paper
• Therapeutic potential of parathyroid hormone

  2004cites this paper
• PerspectiveParathyroid hormone—a drug for orthopedic surgery?

  2004cites this paper
• Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.

  2004cites this paper
• Parathyroid hormone therapy for osteoporosis.

  2003cites this paper
• Teriparatida (PTH[1-34]rh): uma nova perspectiva no tratamento da osteoporose

  2003influential citation
• L’hormone parathyroïdienne dans le traitement de l’ostéoporose

  2003cites this paper
• Genetic Basis for Resistance to Parathyroid Hormone

  2003cites this paper
• CHAPTER 5 – Parathyroid Hormone and Calcium Homeostasis

  2003cites this paper
• Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure.

  2003cites this paper
• Pilot Study with Technosphere/PTH(1 - 34) - A New Approach for Effective Pulmonary Delivery of Parathyroid Hormone (1 - 34)

  2003cites this paper
• The expression of insulin-like growth factor-I mRNA and polypeptide in rat osteoblasts with exposure to parathyroid hormone.

  2003cites this paper
• [Postmenopausal osteoporosis. Clinical practice guide].

  2003cites this paper
• Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.

  2003cites this paper
• Chapter 75 – Parathyroid Hormone

  2002cites this paper
• Peripheral Effects of PTH Are Not Altered after Thyroid Surgery in Euthyroid Patients

  2002cites this paper
• Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH.

  2002cites this paper
• Recent contributions of iliac bone histomorphometry to understanding the anabolic effect of parathyroid hormone

  2002cites this paper
• Effects of the selective oestrogen receptor modulator—raloxifene—on calcium and PTH secretory dynamics in women with osteoporosis

  2001cites this paper
• Primary Hyperparathyroidism and Hyperparathyroid Bone Disease

  2001cites this paper
• Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.

  2001cites this paper
• Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone.

  2001cites this paper
• Six‐Month Daily Administration of Parathyroid Hormone and Parathyroid Hormone—Related Protein Peptides to Adult Ovariectomized Rats Markedly Enhances Bone Mass and Biomechanical Properties: A Comparison of Human Parathyroid Hormone 1–34, Parathyroid Hormone‐Related Protein 1–36, and SDZ‐Parathyroid

  2000cites this paper
• Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

  2000cites this paper
• Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys.

  1999cites this paper
• Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation.

  1999cites this paper
• CHAPTER 46 – Parathyroid Hormone

  1999cites this paper
• Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans.

  1999cites this paper
• Intermittent parathyroid hormone treatment can promote linear growth in the ovariectomized growing rat.

  1999cites this paper
• A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism.

  1998cites this paper
• The prevention and treatment of osteoporosis.

  1998cites this paper
• Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis.

  1998cites this paper
• Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone.

  1998cites this paper
• An Intact N Terminus Is Required for the Anabolic Action of Parathyroid Hormone on Adult Female Rats

  1997cites this paper
• Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion.

  1997cites this paper
• Single‐dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers

  1997cites this paper
• Anabolic effects of estrogen and parathyroid hormone on skeletal tissues: the use of creatine kinase B activity as a response marker.

  1997cites this paper
• Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans.

  1997cites this paper
• Dysregulation of calcium homeostasis after severe burn injury in children: possible role of magnesium depletion.

  1997cites this paper
• The Effect of PTH Antagonist BIM-44002 on Serum Calcium and PTH Levels in Hypercalcemic Hyperparathyroid Patients

  1997cites this paper
• Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.

  1996cites this paper
• Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans.

  1996cites this paper
• Report 2 : PHARMACOKINETICS AND TOXICOKINETICS OF BIO-PHARMACEUTICALS : TECHNICAL PROBLEMS ( Safety assessment of biotechnology-derived pharmaceutical product.)

  1996cites this paper
• Validation and application of an immunoradiometric assay for the determination of human parathyroid hormone fragment 1-34 in dog plasma following subcutaneous and intravenous administration.

  1996cites this paper